Autopsy report · NCT04735575

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

“Company's resource optimization and product's development change”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd.

Sponsor type

Industry

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

EMB-06

Participants

40

Sites

10

Countries

Australia, China

Trials that died the same way

• A Clinical Investigation to Assess the Effectiveness of Benzocaine Condoms in Healthy Adult Men
  “Change of the product development strategy” (76% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (72% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (68% match in meaning)
• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
  “company development strategy adjustment” (68% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.